Prapela
Prapela is a Biddeford, Maine medical device company that has developed the FDA De Novo-authorized SVS Bassinet Pad, delivering Stochastic Vibro-tactile Stimulation to console opioid-exposed newborns with Neonatal Abstinence Syndrome in hospital NICUs.
- Company typePrivate
- Founded2017
- HeadquartersBiddeford, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prapela does
Prapela is a privately held medical device company founded in 2017 and based in Biddeford, Maine. The company has developed the SVS Bassinet Pad, a hardware device that delivers Stochastic Vibro-tactile Stimulation (SVS) — a continuous, randomized pattern of low-level vibrations designed to console and stabilize infants, particularly those exposed to opioids in utero and diagnosed with Neonatal Abstinence Syndrome (NOWS). The technology is clinically validated to console opioid-exposed newborns as effectively as human holding and is intended to operate continuously alongside caregiver protocols within established NOWS scoring frameworks (ESC, Finnegan, or hybrid systems).
The company's go-to-market is enterprise-focused, targeting hospital neonatal intensive care units (NICUs) and maternity wards through a clinical-evidence-based direct sales motion aimed at hospital procurement and clinical decision-makers. The SVS Bassinet Pad received FDA De Novo authorization (DEN240031) on April 4, 2025, establishing the device as a regulated Class II medical device for the specific indication of opioid-exposed newborns. Pricing is not publicly disclosed, and no customers, revenue figures, or distribution partnerships are reported in the available source material.
Prapela has been funded primarily through non-dilutive sources, accumulating approximately $8.2M across grants from the National Institutes of Health (including NIDA), the Charles Hood Foundation, state-level economic development agencies (Ohio Third Frontier, Massachusetts Life Sciences Center, Maine Technology Institute, Southern Maine Planning and Development Commission), and corporate/philanthropic sources including Johnson & Johnson and MassChallenge. The company employs between 1 and 10 people and operates with a small leadership team consisting of CEO and co-founder John Konsin, co-founder and technical advisor Jim Niemi, and VP of Product Development David Morrill.
Prapela firmographics
Firmographics- Name
- Prapela
- Legal name
- Prapela
- Website
- https://prapela.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Prapela is a Biddeford, Maine medical device company that has developed the FDA De Novo-authorized SVS Bassinet Pad, delivering Stochastic Vibro-tactile Stimulation to console opioid-exposed newborns with Neonatal Abstinence Syndrome in hospital NICUs.
- Ownership category
- akta.pro rank
Prapela industry classification
Industry- Product category
- Neonatal Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neonatal Intensive Care & Special Care Nurseries (NICU/SCN) (HLAFAJAE)
Keywords
Where Prapela is headquartered
LocationHeadquarters
- HQ city
- Biddeford
- HQ country
- United States
- HQ region
- North America
Markets served
Prapela business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Others
Revenue model
- SVS Bassinet Pad Device Sales: Medical device revenue from the sale of the SVS bassinet pad system to hospital neonatal units. The device is FDA De Novo authorized for use with opioid-exposed newborns.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Prapela product offering
Product offeringCore offering
Prapela develops and sells the SVS Bassinet Pad, an FDA De Novo authorized medical device that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns and infants with Neonatal Abstinence Syndrome (NOWS). The device operates continuously alongside clinical care teams to stabilize drug-exposed infants as effectively as human holding, while reducing nursing workload in hospital NICU and maternity settings.
Product overview
Prapela offers a single unified product — the SVS Bassinet Pad — which delivers Stochastic Vibro-tactile Stimulation (SVS) technology to assist drug-exposed infants and other newborns with various health issues. The device is FDA De Novo authorized and clinically proven to reduce costs and improve health outcomes for neonatal abstinence syndrome (NOWS) by providing continuous therapy that consoles infants alongside the care team.
Differentiator
Problem solved
Functional benefit
Brands
- SVS Bassinet Pad: A breakthrough therapy device utilizing Stochastic Vibro-tactile Stimulation technology to clinically prove to console opioid-exposed newborns as effectively as holding.
Products and services
- SVS Bassinet Pad An FDA De Novo authorized medical device pad that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns as effectively as human holding. It works continuously alongside the care team within ESC, Finnegan, or hybrid NOWS management frameworks, reducing nursing burden and improving infant stabilization in hospital NICU and maternity settings.
Quantifiable outcome
- Clinically proven to console opioid-exposed newborns as effectively as holding
- +1 more outcomes
Companies that use Prapela
Customer profileSegments1 record
Ideal customer profiles1 record
Prapela technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Prapela partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights5 records
Prapela competitors and assessment
Company assessmentBroad incumbents
- Masimo: Medical technology company with neonatal pulse oximetry and patient monitoring products sold into hospital NICUs. Comparable in regulatory-cleared, evidence-based neonatal device sales, though focused on monitoring rather than soothing.
- Natus Medical: Established medical device company with a broad neonatal and neurology product portfolio, including NICU screening and monitoring devices. Overlaps with Prapela in serving hospital neonatal units and pursuing regulatory-cleared devices for newborn care.
- Drägerwerk: Global manufacturer of NICU incubators, warmers, and neonatal respiratory care equipment. Comparable as a hospital-channel medical device vendor addressing neonatal intensive care workflows, though Prapela operates in a far more focused niche.
- Fisher & Paykel Healthcare: Listed respiratory and neonatal care device company selling infant warming, CPAP, and humidification products into NICUs worldwide. Comparable hospital sales motion and regulatory pathway, but much broader product portfolio.
- GE HealthCare: Large incumbent selling NICU incubators, warmers, and patient monitoring into hospitals globally. Comparable as a hospital-channel neonatal device vendor with established GPO contracts.
- Philips (Mother & Child Care): Major healthcare technology vendor with neonatal monitoring, warming, and NICU informatics offerings. Comparable as a NICU capital equipment competitor with established hospital procurement relationships.
Regional players
- Atom Medical Corporation: Japanese manufacturer specializing in neonatal and obstetric medical equipment, including incubators and bassinets. Comparable as a focused neonatal medical device vendor, though primarily serving Asia-Pacific markets.
Emerging players
- Phoenix Medical Systems: Manufacturer of neonatal and infant care equipment (incubators, bassinets, phototherapy). Comparable as a focused neonatal medical device maker targeting hospital customers.
- Inspirational Healthcare (SLE/Inspiration Healthcare): Specialist neonatal medical device company selling ventilators and infant care equipment into NICUs. Comparable as a focused neonatal device vendor with similar hospital sales motion.
- Medela: Company with neonatal and NICU product lines including feeding support and breast milk solutions sold into hospitals. Partial overlap in NICU channel and newborn care category, though focused on feeding rather than soothing.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
Prapela social profiles
Digital presencePrapela compliance and trust
Trust signalCompliance1 record
Prapela financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prapela leadership team
Management profileNumber of profiles
Profiles3 records
Prapela funding detail
Funding detailFunding overview
Funding rounds17 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prapela M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prapela
What does Prapela do?
Prapela develops and sells the SVS Bassinet Pad, an FDA De Novo authorized medical device that delivers Stochastic Vibro-tactile Stimulation (SVS) to console opioid-exposed newborns and infants with Neonatal Abstinence Syndrome (NOWS). The device operates continuously alongside clinical care teams to stabilize drug-exposed infants as effectively as human holding, while reducing nursing workload in hospital NICU and maternity settings.
Is Prapela a public or private company?
Prapela is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Prapela founded?
Prapela was founded in 2017. It employs 1 to 10 people.
Where is Prapela based?
Prapela is headquartered in Biddeford, United States, in the North America region.
How does Prapela make money?
One revenue line is on record: SVS Bassinet Pad Device Sales.
Who are Prapela's main competitors?
Broad incumbents on record are Masimo, Natus Medical, Drägerwerk, Fisher & Paykel Healthcare, GE HealthCare and Philips (Mother & Child Care). Atom Medical Corporation is listed as a regional player. Emerging players are Phoenix Medical Systems, Inspirational Healthcare (SLE/Inspiration Healthcare) and Medela.
Does Prapela have an API?
No public API is recorded for Prapela.
What industry is Prapela in?
Prapela's product category is Neonatal Medical Devices. Its primary akta.pro industry code is HLAFAJAE, Neonatal Intensive Care & Special Care Nurseries (NICU/SCN). Its NAICS code is 339113 and its SIC code is 3845.